Y-incision aortic annular enlargement after surgical explantation of transcatheter aortic valve bioprosthesis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. TAVR Explant in the Era of Lifetime Valve Management: Indications, Operative Challenges, and Contemporary Outcomes.Current cardiology reports · 2026
   Review
2. Expanding indications, narrowing margins: the renewed importance of aortic annular enlargement in the valve-in-valve era.Journal of visualized surgery · 2026
   Article
3. Surgical vs. Medical Management of Infective Endocarditis Following TAVR: A Systematic Review and Meta-Analysis.Journal of cardiovascular development and disease · 2025
   Review

Corrections and comments

• Commented on by
  Expanding indications, narrowing margins: the renewed importance of aortic annular enlargement in the valve-in-valve era.2026

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.